Katja Thümmler, Claudia Wrzos, Jonas Franz, Daniel McElroy, John J Cole, Lorna Hayden, Diana Arseni, Friedrich Schwarz, Andreas Junker, Julia M Edgar, Sebastian Kügler, Andreas Neef, Fred Wolf, Christine Stadelmann, Christopher Linington
AIMS: Fibroblast growth factor (FGF) signalling is dysregulated in multiple sclerosis (MS) and other neurological and psychiatric conditions, but there is little or no consensus as to how individual FGF family members contribute to disease pathogenesis. Lesion development in MS is associated with increased expression of FGF1, FGF2 and FGF9, all of which modulate remyelination in a variety of experimental settings. However, FGF9 is also selectively upregulated in major depressive disorder (MDD) prompting us to speculate it may also have a direct effect on neuronal function and survival...
September 13, 2023: Neuropathology and Applied Neurobiology